Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres |
| |
| Affiliation: | 1. Gastroenterology Service, ASL BAT, Andria, BT, Italy;2. Division of Gastroenterology, ASL Roma H, Albano Laziale, Rome, Italy;3. Division of Surgery, “P. Colombo” Hospital, Velletri, Rome, Italy;4. Division of Gastroenterology, “San Paolo” Hospital, Bari, Italy;5. Division of Gastroenterology, “Cristo Re” Hospital, Rome, Italy;6. Digestive Endoscopy Unit, “Santa Maria Goretti” Hospital, Latina, Italy;7. Digestive Endoscopy and Nutrition Unit, “S. Eugenio” Hospital, Rome, Italy;8. Division of Gastroenterology, “Belcolle Hospital”, Viterbo, Italy;1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, IRCCS Cà Granda Ospedale Maggiore Foundation, Milano, Italy;2. Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Italy;3. Department of Pharmacological Sciences and Biomolecular, University of Milan, Milan, Italy;4. IRCCS Multimedica, Milano, Italy;1. The Bruce and Ruth Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel;2. Heart Failure Unit, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Lin Medical Center, Haifa, Israel;3. Heart Failure Clinic, Lin Medical Center, Haifa, Israel;4. Cardiovascular Department, Poriya Medical Center, Tiberius, Israel;1. Department of Geriatric Medecine, Centre Hospitalier Universitaire Nord, Marseille, France;2. Department of Cardiology, Centre Hospitalier Universitaire Nord, Marseille, France |
| |
| Abstract: | BackgroundInfliximab (IFX) and adalimumab (ADA) are the key treatments for Crohn's Disease (CD), unresponsive to standard treatments. Our aim was to compare the efficacy and safety of IFX and ADA in treating CD in clinical practice.MethodsOne hundred and twenty-six patients (61 M, 65 F, mean age 36.2 years, range 19–67 years), affected by CD, were treated with infliximab (IFX, 59 patients) or adalimumab (ADA, 66 patients). Clinical efficacy, mucosal healing (MH), histological healing (HH), and safety were assessed. MH was defined complicated if healing of ulcers occurred with deformation of bowel profile and/or complete colonoscopy was impossible because of scars.ResultsPatients were followed-up for 36 months. No difference was found between IFX and ADA in maintaining long-term clinical remission, MH and HH. Complicated MH was present in 17 (28.8%) patients in IFX group and in 7 (10.6%) patients in ADA group (p = 0.012). In 9 (15.2%) patients in IFX group and 2 (3.0%) patients in ADA group colonoscopy was incomplete without cecal intubation or terminal ileum exploration (p = 0.024).Side effects were similar in both groups.ConclusionsBoth IFX and ADA seem to be effective and safe in long-term outpatient treatment of CD in clinical practice. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
